Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, open-label, phase I clinical trial aimed to evaluate the safety and efficacy of DLL3-CAR-NK cells treatment for relapsed and refractory extensive small cell lung cancer (ES-SCLC).


Clinical Trial Description

This study is a multicenter, single arm, open-label, non randomized, single dose, dose escalation, phase I clinical trial on relapsed and refractory ES-SCLC. The phase I clinical trial will be conducted according to the principle of "3 + 3". Three dose groups will be set up, namely group A: 1.0 × 10^7, group B: 1.0 × 10^8, and group C: 1.0 × 10^9 DLL3-CAR-NK cells. 9-18 subjects will be enrolled in the groups and given a single infusion of DLL3-CAR-NK cells injection in order to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), evaluate the safety and efficacy of the cell infusion. It well be recommend dose for phase II clinical study (recommended phase II dose, RP2D). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05507593
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact Liang Liu, M.D
Phone 86-22-23340123
Email liuliang@tjmuch.com
Status Recruiting
Phase Phase 1
Start date September 1, 2022
Completion date July 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05299255 - Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer Phase 2
Recruiting NCT04731909 - Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer N/A
Recruiting NCT04660097 - Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer Phase 2
Completed NCT05116007 - Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC Phase 1
Active, not recruiting NCT04221529 - Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide Phase 2
Recruiting NCT04654364 - Lung Cancer Registry